Hospital burden of gout, pseudogout and other crystal arthropathies in France.

[1]  Y. Tung,et al.  Prevalence of gout with comorbidity aggregations in southern Taiwan. , 2015, Joint, bone, spine : revue du rhumatisme.

[2]  L. Carmona,et al.  Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout , 2013, Annals of the rheumatic diseases.

[3]  A. Wertheimer,et al.  A Revised Estimate of the Burden of Illness of Gout☆ , 2013, Current therapeutic research, clinical and experimental.

[4]  L. Punzi,et al.  Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. , 2013, Joint, bone, spine : revue du rhumatisme.

[5]  H. Sayles,et al.  Gout‐Related Health Care Utilization in US Emergency Departments, 2006 Through 2008 , 2013, Arthritis care & research.

[6]  M. Doherty,et al.  Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study , 2012, Annals of the rheumatic diseases.

[7]  T. Merriman,et al.  Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009. , 2013, Rheumatology.

[8]  L. Roberts,et al.  Healthcare burden of in‐hospital gout , 2012, Internal medicine journal.

[9]  A. Forsythe,et al.  Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy , 2012, American journal of therapeutics.

[10]  A. Saraux,et al.  GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics (n = 1003). , 2012, Joint, bone, spine : revue du rhumatisme.

[11]  B. Arroll,et al.  National prevalence of gout derived from administrative health data in Aotearoa New Zealand. , 2012, Rheumatology.

[12]  K. Rascati,et al.  Evaluation of health care costs and utilization patterns for patients with gout. , 2012, Clinical therapeutics.

[13]  Giuseppe Turchetti,et al.  The economic impact of gout: a systematic literature review. , 2012, Clinical and experimental rheumatology.

[14]  L. Harrold,et al.  Impact of Deficits in Gout Care on Hospitalizations , 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[15]  G. Reach.  Treatment adherence in patients with gout. , 2011, Joint, bone, spine : revue du rhumatisme.

[16]  Hyon K. Choi,et al.  Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. , 2011, Arthritis and rheumatism.

[17]  I. Sketris,et al.  Gout in the Elderly — A Population Health Study , 2009, The Journal of Rheumatology.

[18]  M. Fuldeore,et al.  The Effect of Serum Urate on Gout Flares and Their Associated Costs: An Administrative Claims Analysis , 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[19]  E. Krishnan,et al.  Disease-Related and All-Cause Health Care Costs of Elderly Patients With Gout , 2008, Journal of managed care pharmacy : JMCP.

[20]  V. Strand,et al.  Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans , 2007, Annals of the rheumatic diseases.

[21]  L. Annemans,et al.  Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005 , 2007, Annals of the rheumatic diseases.

[22]  S. Kong,et al.  A literature review of the epidemiology and treatment of acute gout. , 2003, Clinical therapeutics.